Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections.

Walaiporn WangchindaJason M Pogue Visanu ThamlikitkulPannee LeelawattanachaiPornpan KoomanachaiManjunath Amit P Pai

Published in: The Journal of antimicrobial chemotherapy (2024)

A fosfomycin dosage of 15 g/day with adjustment according to kidney function provided high PTA and CFR when treating E. coli. This dosage is lower than that used in current practice and may improve tolerability. Higher dosages may be needed for P. aeruginosa; however, safety data are limited.

Keyphrases

gram negative
multidrug resistant
primary care
escherichia coli
healthcare
electronic health record
open label
urinary tract infection
clinical trial
machine learning
quality improvement
combination therapy